Eli Lilly has introduced a limited early-access program for retatrutide, allowing certain patients with severe, treatment-resistant obesity to be considered for the investigational drug before FDA approval. The program, officially titled Pre-approval Expanded Access of Retatrutide (LY3437943), is registered on ClinicalTrials.gov under NCT07629401 and is listed as available as of its August 6, 2026 update.
The announcement represents an important development in retatrutide’s clinical research program. However, early access does not mean retatrutide has received FDA approval or is available to the general public.
Eli Lilly’s expanded-access pathway is intended for a limited number of patients with serious medical complications who cannot participate in ongoing clinical trials and have not achieved adequate results from approved treatment options.
According to reporting by Reuters on August 3, 2026, Lilly confirmed that it had established the program and was reviewing requests submitted by healthcare professionals.
This article explains who qualifies for Eli Lilly retatrutide early access, how the application process works, the latest program status, and what the development means for retatrutide research in 2026.
Official program: ClinicalTrials.gov — NCT07629401
What Is Eli Lilly’s Retatrutide Early Access Program?
The retatrutide early-access program is an expanded-access arrangement that may provide investigational retatrutide to eligible individuals outside conventional clinical trials.
Expanded access, sometimes called compassionate use, is a regulated pathway allowing certain patients with serious or life-threatening conditions to receive investigational treatments when satisfactory alternatives are unavailable.
Unlike a traditional clinical trial, expanded access is primarily intended to provide treatment to an individual patient rather than to answer a clinical research question.
The retatrutide program has the following official details:
| Program information | Official details |
|---|---|
| Program name | Pre-approval Expanded Access of Retatrutide (LY3437943) |
| ClinicalTrials.gov ID | NCT07629401 |
| Sponsor | Eli Lilly and Company |
| Program type | Individual-patient expanded access |
| First publicly posted | June 5, 2026 |
| Latest posted update | August 6, 2026 |
| Listed availability | Available |
| Minimum age | 18 years |
| Relevant condition | Severe, treatment-resistant obesity with serious complications |
The registry’s “Available” designation indicates that the program is listed as available for consideration. It does not mean every applicant will receive access.
Source: Official Retatrutide Expanded Access Registration
August 2026 Update: Eli Lilly Confirms Limited Retatrutide Access
On August 3, 2026, Reuters reported that Eli Lilly would allow a limited number of eligible patients to access investigational retatrutide before potential FDA approval.
The company confirmed that it had developed an expanded-access program and was actively reviewing requests from healthcare professionals.
This followed earlier reporting about a 79-year-old patient who had received special access to retatrutide.
The program represents a restricted medical pathway rather than a commercial product launch.
It also does not mean that retatrutide can be obtained through retail pharmacies, online peptide sellers, or ordinary prescriptions.
Source: Reuters — Eli Lilly to Offer Early Access to Retatrutide, August 3, 2026
Who Qualifies for Eli Lilly Retatrutide Early Access?
According to the ClinicalTrials.gov registration, patients must meet several specific criteria to be considered.
1. Adults Aged 18 or Older
The program is restricted to adults.
Applicants must be at least 18 years old when evaluated for eligibility.
2. Severe Obesity With a BMI of at Least 35
The program requires a body mass index (BMI) of 35 kg/m² or higher.
However, meeting this threshold alone is not sufficient.
The applicant must also have severe obesity that has not responded adequately to approved chronic weight-management treatment, despite adherence to and tolerance of the highest available treatment dose.
3. At Least Two Serious Obesity-Related Complications
Applicants must have at least two serious or life-threatening obesity-related complications.
They must also be receiving standard medical care for those complications.
The public registration does not establish that any particular combination of medical conditions automatically qualifies a person.
Individual assessment remains necessary.
4. Unable to Participate in an Ongoing Clinical Trial
A central requirement is that the patient cannot participate in an ongoing retatrutide clinical trial or a comparable investigational treatment study.
Reasons may include:
- Not meeting a trial’s eligibility criteria.
- No reasonably accessible clinical trial site.
- Other trial-related barriers covered by the program’s eligibility framework.
Expanded access is not intended to replace clinical trial participation when an appropriate trial is available.
5. Standard Treatment Options Must Have Been Considered
The registration requires that standard treatment options, including bariatric surgery, have been discussed with the patient through shared decision-making.
The program is intended for patients with limited satisfactory treatment options rather than individuals seeking an alternative to standard care without medical evaluation.
6. No Medical Contraindication to Retatrutide
The official criteria exclude individuals with a medical contraindication to retatrutide therapy.
The treating physician and Lilly must evaluate the potential benefits and risks in the individual patient’s circumstances.
Meeting the general criteria does not guarantee that an application will be approved.
Source: ClinicalTrials.gov — Expanded Access Eligibility Criteria
How Can Patients Apply for Retatrutide Early Access?
Eli Lilly specifies that expanded-access requests must be initiated by the patient’s treating physician.
Patients and caregivers should discuss eligibility with their physician rather than attempting to submit an independent application directly to Lilly.
The documented process involves several stages.
Step 1: Evaluation by a Treating Physician
The physician reviews the patient’s medical history, existing treatments, serious obesity-related complications, and potential eligibility for available clinical trials.
Step 2: Physician Contacts Eli Lilly
If the physician believes expanded access may be appropriate, they can contact Eli Lilly through its established medical inquiry process.
The official registration lists:
Eli Lilly physician inquiries
- Phone: 1-800-LillyRx (1-800-545-5979)
- Email: ClinicalTrials@lilly.com
These are listed for professional inquiries relating to clinical trials and expanded access. Patients are directed to work through their treating physicians.
Step 3: Lilly Reviews the Request
The company assesses the individual case, considering clinical eligibility, available scientific information, product supply, and geographic availability.
Lilly’s general expanded-access policy states that it responds to physician requests within five business days after receiving the required information. That response is not a guarantee of approval or treatment availability.
Step 4: Regulatory and Ethics Requirements
If Lilly agrees to support the request, the applicable FDA expanded-access procedures must also be completed.
In the United States, this generally involves FDA review, institutional review board (IRB) oversight, and informed consent.
The FDA provides a specific submission process for physicians requesting investigational drugs for individual patients.
Step 5: Medical Supervision
When all applicable requirements have been satisfied, investigational treatment is provided under the supervision of the treating physician.
It is not a retail purchase or an ordinary prescription.
Sources:
Is Retatrutide Early Access the Same as a Clinical Trial?
No. Although both pathways can involve an investigational medication, they serve different purposes.
| Feature | Clinical trial | Expanded access |
|---|---|---|
| Primary purpose | Evaluate safety and effectiveness | Provide investigational treatment in exceptional circumstances |
| Eligibility | Defined by study protocol | Based on medical need and access criteria |
| Availability | At participating study sites | Considered individually |
| FDA approval of the drug | Not required for investigational trial use | Not required, but regulatory authorization applies |
| Medical monitoring | Study investigators | Treating physician |
| Access guaranteed | No | No |
Eli Lilly encourages participation in clinical trials whenever possible.
Researchers and prospective participants can review official studies through Lilly’s Clinical Trial Finder.
Why Did Eli Lilly Introduce Retatrutide Early Access?
The stated purpose of the program is to provide a possible pathway for a limited number of patients with severe medical needs who cannot participate in available trials.
In its expanded-access policy, Lilly explains that it may consider supplying investigational medicines outside clinical trials when several conditions are met.
These include serious or life-threatening illness, the absence of satisfactory alternatives, a medically justified benefit-risk assessment, and the requirement that expanded access not interfere with clinical development.
The company has not characterized the retatrutide program as a general early-launch initiative.
Accordingly, the program should not be interpreted as a commercial distribution strategy or evidence that regulatory approval has been granted.
What Do Eli Lilly’s Retatrutide Clinical Trials Show?
Retatrutide is an investigational triple hormone receptor agonist.
It activates three receptor systems:
- GLP-1
- GIP
- Glucagon
Its combined receptor activity is being investigated for effects on metabolic regulation and related clinical outcomes.
In a Phase 2 obesity trial published in the New England Journal of Medicine in 2023, the highest investigational treatment group experienced a mean body-weight reduction of 24.2% at 48 weeks, compared with 2.1% in the placebo group.
Subsequent Phase 3 studies have examined retatrutide in populations with obesity, type 2 diabetes, and obesity-associated conditions.
However, trial results do not establish that the medication is suitable for every individual, nor do they eliminate uncertainties about long-term safety.
Published Phase 2 study: Jastreboff et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity
For a detailed review of ongoing and completed studies, explore our educational coverage of Eli Lilly retatrutide clinical trials.
Is Retatrutide FDA Approved in November 2026?
No.
As of November 10, 2026, retatrutide remains an investigational medicine.
According to Eli Lilly’s official retatrutide information page, the compound has not received FDA approval or approval from another regulatory agency.
In August 2026, Reuters reported that Lilly planned to seek FDA approval in the first quarter of 2027.
A planned regulatory submission does not guarantee approval, and the FDA must assess the supporting evidence before making its decision.
Expanded access does not change the investigational status of the drug.
Source: Eli Lilly — What to Know About Retatrutide
Does Early Access Mean Retatrutide Is Available to Buy Online?
No.
Eli Lilly’s expanded-access program is a controlled medical pathway for selected patients, not authorization for commercial retailers to sell retatrutide for human use.
The company specifically warns about unauthorized products marketed as retatrutide through online sellers and social media.
Such products may not have the same identity, formulation, manufacturing quality, or testing as the investigational pharmaceutical product administered during Lilly’s clinical trials.
Eli Lilly’s early-access program does not include independent research-chemical retailers or make their products equivalent to its investigational drug.
Source: Eli Lilly — Identifying Authentic Medicines and Unapproved Products
What Does This Development Mean for Peptide Research?
The expanded-access program reflects an additional stage in retatrutide’s clinical development.
It demonstrates that Lilly has established a formal mechanism to consider exceptional requests for access before potential regulatory approval.
For the scientific community, the broader retatrutide development program continues to generate research questions involving receptor pharmacology, metabolic signaling, clinical safety, and long-term outcomes.
However, the existence of an early-access program does not establish the compound’s safety or effectiveness for the general population.
Researchers must continue to distinguish between controlled clinical investigations, medical expanded access, and nonclinical laboratory research.
At Neuro Peptide, our educational resources discuss the molecular characteristics and published scientific literature concerning research peptides, including retatrutide.
Neuro Peptide is not affiliated with Eli Lilly, does not participate in Lilly’s expanded-access program, and does not supply the investigational pharmaceutical product used in that program.
Frequently Asked Questions
Is Eli Lilly offering early access to retatrutide in 2026?
Yes. Eli Lilly has established a single-patient expanded-access program registered as NCT07629401. Its latest posted ClinicalTrials.gov update, dated August 6, 2026, lists the program as available.
Who is eligible for retatrutide compassionate use?
The program is intended for adults aged 18 or older with a BMI of at least 35, at least two serious or life-threatening obesity-related complications, insufficient response to approved chronic weight-management therapy, and inability to participate in a relevant clinical trial. Other criteria and individual medical review also apply.
Can a patient apply directly for retatrutide early access?
No. Eli Lilly specifies that requests must be initiated by the patient’s treating physician.
Is retatrutide compassionate use free?
The publicly available program registration does not establish that all treatment, administrative, medical monitoring, and related costs are covered. Patients should discuss financial considerations with their treating physician and the responsible program representatives.
Does early access mean retatrutide will be approved soon?
No. Expanded access does not predict an approval decision or establish a guaranteed approval date.
Can anyone with obesity receive early access?
No. The program has restrictive medical eligibility requirements and is intended for a limited patient population.
Is the retatrutide expanded-access program available outside the United States?
The public registration does not identify a guaranteed list of eligible countries. Eli Lilly states that availability depends partly on geography and applicable regulatory requirements.
Where can I find the official retatrutide early-access program?
The official registration is available at ClinicalTrials.gov — NCT07629401.
Conclusion: Eli Lilly Retatrutide Early Access in 2026
Eli Lilly’s retatrutide early-access program is a documented development in the investigational drug’s clinical pathway.
Registered in June 2026 and publicly confirmed in August, the program provides a potential route for selected adults with severe, treatment-resistant obesity and serious medical complications.
However, eligibility is highly restricted, applications require physician involvement, and participation depends on individual review and regulatory requirements.
As of November 2026, retatrutide remains investigational and unavailable for general commercial medical use.
For scientists and researchers following retatrutide’s development, the expanded-access program adds another dimension to its ongoing clinical investigation.
Visit Neuro Peptide for educational resources covering retatrutide’s molecular mechanisms, receptor biology, and other areas of peptide research.
References
- ClinicalTrials.gov (2026). Pre-approval Expanded Access of Retatrutide (LY3437943). NCT07629401. https://clinicaltrials.gov/study/NCT07629401
- Reuters (August 3, 2026). Eli Lilly to Offer Early Access to Next-Generation Obesity Drug to Some Patients. https://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
- Eli Lilly and Company. Expanded Access and Compassionate Use Policy. https://www.lilly.com/science/clinical-trials/expanded-access
- U.S. Food and Drug Administration. Expanded Access: Information for Patients. https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients
- U.S. Food and Drug Administration. A Guide to Non-emergency Single Patient Expanded Access Submissions. https://www.fda.gov/drugs/investigational-new-drug-application-ind/physicians-guide-non-emergency-single-patient-expanded-access-submissions
- Eli Lilly and Company (October 2026). What to Know About Retatrutide. https://www.lilly.com/news/stories/what-to-know-about-retatrutide
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972
Disclaimer: This article provides general educational information and is not medical advice. Retatrutide remains investigational. Expanded-access eligibility and treatment decisions require qualified medical and regulatory review. Neuro Peptide is independent of Eli Lilly and is not an authorized source of retatrutide for human treatment.